IL274522A - 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors - Google Patents
2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitorsInfo
- Publication number
- IL274522A IL274522A IL274522A IL27452220A IL274522A IL 274522 A IL274522 A IL 274522A IL 274522 A IL274522 A IL 274522A IL 27452220 A IL27452220 A IL 27452220A IL 274522 A IL274522 A IL 274522A
- Authority
- IL
- Israel
- Prior art keywords
- syk
- carboxamides
- pyrimidin
- diamino
- jak kinases
- Prior art date
Links
- VULZVYGZVOMUKU-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carboxamide Chemical class NC(=O)C1=CN=C(N)N=C1N VULZVYGZVOMUKU-UHFFFAOYSA-N 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4540608P | 2008-04-16 | 2008-04-16 | |
| US4541708P | 2008-04-16 | 2008-04-16 | |
| US4539908P | 2008-04-16 | 2008-04-16 | |
| US12034808P | 2008-12-05 | 2008-12-05 | |
| US12034108P | 2008-12-05 | 2008-12-05 | |
| US12034408P | 2008-12-05 | 2008-12-05 | |
| PCT/US2009/002420 WO2009145856A1 (en) | 2008-04-16 | 2009-04-16 | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL274522A true IL274522A (en) | 2020-06-30 |
Family
ID=43570275
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL208637A IL208637A (en) | 2008-04-16 | 2010-10-11 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| IL251655A IL251655B (en) | 2008-04-16 | 2017-04-09 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| IL274522A IL274522A (en) | 2008-04-16 | 2020-05-07 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL208637A IL208637A (en) | 2008-04-16 | 2010-10-11 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
| IL251655A IL251655B (en) | 2008-04-16 | 2017-04-09 | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| AU (1) | AU2009251863B2 (en) |
| BR (1) | BRPI0910560B8 (en) |
| CO (1) | CO6331433A2 (en) |
| CY (1) | CY1118559T1 (en) |
| DK (1) | DK2321283T3 (en) |
| ES (1) | ES2597441T3 (en) |
| GT (1) | GT201000298A (en) |
| HU (1) | HUE031638T2 (en) |
| IL (3) | IL208637A (en) |
| LT (1) | LT2321283T (en) |
| MX (1) | MX353206B (en) |
| NI (1) | NI201000176A (en) |
| NZ (1) | NZ589314A (en) |
| PL (1) | PL2321283T3 (en) |
| PT (1) | PT2321283T (en) |
| SI (1) | SI2321283T1 (en) |
| ZA (1) | ZA201007045B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| AU2013202496B2 (en) * | 2008-06-27 | 2016-08-04 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| MY160734A (en) | 2010-08-10 | 2017-03-15 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| CA3224094A1 (en) * | 2021-03-09 | 2022-09-15 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Use of tricyclic heteroaryl-containing compound |
| CN114196651B (en) * | 2021-12-15 | 2023-06-30 | 中国林业科学研究院亚热带林业研究所 | New application of D6 protein kinase D6PKL2 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69839735D1 (en) * | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | PYRIMIDINE-5-carboxamide DERIVATIVES |
| JP4529685B2 (en) * | 2002-06-28 | 2010-08-25 | アステラス製薬株式会社 | Diaminopyrimidine carboxamide derivatives |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
-
2009
- 2009-04-16 SI SI200931540A patent/SI2321283T1/en unknown
- 2009-04-16 LT LTEP09755219.4T patent/LT2321283T/en unknown
- 2009-04-16 ES ES09755219.4T patent/ES2597441T3/en active Active
- 2009-04-16 PT PT97552194T patent/PT2321283T/en unknown
- 2009-04-16 HU HUE09755219A patent/HUE031638T2/en unknown
- 2009-04-16 BR BRPI0910560A patent/BRPI0910560B8/en active IP Right Grant
- 2009-04-16 MX MX2010011464A patent/MX353206B/en active IP Right Grant
- 2009-04-16 DK DK09755219.4T patent/DK2321283T3/en active
- 2009-04-16 NZ NZ589314A patent/NZ589314A/en not_active IP Right Cessation
- 2009-04-16 PL PL09755219T patent/PL2321283T3/en unknown
- 2009-04-16 AU AU2009251863A patent/AU2009251863B2/en active Active
-
2010
- 2010-10-04 ZA ZA2010/07045A patent/ZA201007045B/en unknown
- 2010-10-11 IL IL208637A patent/IL208637A/en active IP Right Grant
- 2010-10-15 GT GT201000298A patent/GT201000298A/en unknown
- 2010-10-15 NI NI201000176A patent/NI201000176A/en unknown
- 2010-11-16 CO CO10143190A patent/CO6331433A2/en active IP Right Grant
-
2016
- 2016-10-13 CY CY20161101026T patent/CY1118559T1/en unknown
-
2017
- 2017-04-09 IL IL251655A patent/IL251655B/en active IP Right Grant
-
2020
- 2020-05-07 IL IL274522A patent/IL274522A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NI201000176A (en) | 2011-08-08 |
| HUE031638T2 (en) | 2017-07-28 |
| AU2009251863B2 (en) | 2014-09-25 |
| BRPI0910560B8 (en) | 2023-03-21 |
| PT2321283T (en) | 2016-10-19 |
| BRPI0910560A2 (en) | 2021-04-27 |
| BRPI0910560B1 (en) | 2023-01-24 |
| IL251655B (en) | 2020-05-31 |
| MX2010011464A (en) | 2014-06-16 |
| IL208637A0 (en) | 2010-12-30 |
| DK2321283T3 (en) | 2016-10-31 |
| ZA201007045B (en) | 2012-08-29 |
| AU2009251863A1 (en) | 2009-12-03 |
| IL208637A (en) | 2017-04-30 |
| AU2009251863A2 (en) | 2011-06-09 |
| CY1118559T1 (en) | 2017-07-12 |
| HK1158179A1 (en) | 2012-07-13 |
| CO6331433A2 (en) | 2011-10-20 |
| GT201000298A (en) | 2014-05-07 |
| ES2597441T3 (en) | 2017-01-18 |
| LT2321283T (en) | 2016-12-12 |
| NZ589314A (en) | 2012-10-26 |
| MX353206B (en) | 2018-01-08 |
| PL2321283T3 (en) | 2017-01-31 |
| SI2321283T1 (en) | 2017-01-31 |
| IL251655A0 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG2014015085A (en) | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
| ZA201007046B (en) | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
| IL274522A (en) | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
| IL211693A0 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| ZA201008808B (en) | Novel phenylpyrazinones as kinase inhibitors | |
| IL206394A0 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| IL210207A0 (en) | Compounds having antiviral properties | |
| IL194424A0 (en) | 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors | |
| PT2231642E (en) | Pyrimidines as kinase inhibitors | |
| SI2187759T1 (en) | Erythritol-based hard coatings | |
| GB0718255D0 (en) | Nucleobase characterisation | |
| IL210573A0 (en) | Compounds as kinase inhibitors | |
| ZA201008878B (en) | Naphthyridiniones as aurora kinase inhibitors | |
| GB0710113D0 (en) | Authentication of articles | |
| AU2008903407A0 (en) | Compounds having antiviral properties |